Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-β-D-arabinofuranosylcytosine conjugates

Anti-Cancer Drug Design

Volumn 11, Issue 6, 1996, Pages 451-462

  Schott, Herbert ^a   Schwendener, Reto A ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antitumor agents; L1210 murine leukemia; Liposomes; Phospholipid araC conjugates; Phosphotriester method

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CYTARABINE DERIVATIVE; PHOSPHOLIPID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA L 1210; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DRUG CARRIERS; FEMALE; LEUKEMIA L1210; LIPOSOMES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MOLECULAR STRUCTURE; PHOSPHOLIPIDS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; MURINAE;

EID: 0029742765     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. 4-acyl-1-β-D-arabinofuranosylcytosine. Cancer Research, 36, 2726.
2. BERDEL, W.E , OKAMOTO, S., DANHAUSER-RIEDL, S., HONG, C.I., WINTON, E.F., WEST, C.R , RASTETTER, J. & VOGLER, W.R. (1989). Therapeutic activity of 1-β-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice. Experimental Hematology, 17, 364.
3. FORSSEN, E.A., COULTER, D M. & PROFFITT, R.T (1992). Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Research, 52, 3255.
4. HONG, C.I., NECHAEV, A., KIRISITS, A.J., VIG, R., HUI, S.W. & WEST, C.R. (1995). Nucleoside conjugates, 14. Synthesis and antitumor activity of 1-β-D-arabinofuranosylcytosine conjugates of ether lipids with improved water solubility. Journal of Medicinal Chemistry, 38, 1629.
5. HONG, C.I., BERNACKI, R.J., HUI, S.W., RUSTUM, Y. & WEST, C.R. (1990). Formulation, stability, and antitumor activity of 1-β-D-arabinofuranosylcytosine conjugate of thioether phospholipid. Cancer Research, 50, 4401.
6. HONG, C.I., AN, S.H., SCHLISELFELD, L., BUCHHEIT, D.J. NECHAEV, A., KIRISITS, A.J. & WEST, C.R. (1988). Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-β-D-arabinofuranosylcytosine 5′-diphosphate-1,2-dipalmitins. Journal of Medicinal Chemistry, 31, 1793.
7. HONG, C.I., AN, S.H., BUCHHEIT, D.J., NECHAEV, A., KIRISITS, A.J. WEST, C.R. & BERDEL W.E. (1986). Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-β-D-arabinofuranosylcytosine conjugates of ether lipids. Journal of Medicinal Chemistry, 29, 2038.
8. 4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. British Journal of Cancer, 71, 957.
9. 4-hexadecyl-1-β-D-arabinofuranosylcytosine in human leukemic cell lines K-562 and U-937. Cancer Chemotherapy and Pharmacology, 36, 483.
10. 4-hexadecyl-1-β-D-arabinofuranosylcytosine. British Journal of Cancer, 72, 1067.
11. 4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC). incorporated into liposomes. Journal of Pharmacy and Pharmacology, 47, 282.
12. LOHMEYER, M. & BITTMAN, R. (1994). Antitumor ether lipids and alkylphosphocholines. Drugs of the Future, 19, 1021.
13. MATSUSHITA, T , RYU, E.K., HONG, C I., & MACCOSS, M. (1981). Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability. Cancer Research, 41, 2707.
14. RUBAS, W., SUPERSAXO, A., WEDER, H.G., HARTMANN, H R , HENGARTNER, H., SCHOTT, H. & SCHWENDENER, R.A. (1986). Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. International Journal of Cancer, 37, 149.
15. RYU, E.K., ROSS, R.J., MATSUSHITA, T., MACCOSS, M., HONG, C.I & WEST, C R. (1982). Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-β-D-arabinofuranosylcytosine 5′-monophosphate-L-1,2-dipalmitin and selected 1-β-D-arabinofuranosylcytosine 5′-diphosphate-L-1,2-diacylglycerols. Journal of Medicinal Chemistry, 25, 1322.
16. 4-palmitoyl-1-β-D-arabinofuranosylcytosine) conjugates and evaluation of their cytostatic activity against L1210 murine leukemia. Liebigs Annals of Chemistry, 365-369.
17. SCHOTT H., SEMMLER R., CLOSS K. & ECKSTEIN H. (1987). Preparative synthesis of guanylate-rich fragments of the terminal sequence of macronuclear DNA from hypotrichous ciliates using the phosphotriester method in solution. Macromolecular Chemistry, 188, 1313.
18. 4-hexadecyl-1-β-D-arabinofuranosylcytosine. International Journal of Cancer, 51, 466.
19. 4-octadecyl-ara-C, NOAC. Drugs of the Future, 20, 11.
20. 4-octadecyl-1-β-D-arabinofuranosylcytosine in liposomal preparations. Journal of Liposome Research, 5, 27.
21. 4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine. Journal of Cancer Research and Clinical Oncology, 122, 102.
22. SONVEAUX, E. (1986). The organic chemistry underlying DNA synthesis. Bioorganic Chemistry, 14, 274.
23. SUPERSAXO, A., RUBAS, W., HARTMANN, H.R., SCHOTT, H., HENGARTNER, H. & SCHWENDENER, R.A. (1988). The antitumour effect of lipophilic derivatives of 5-fluoro-2′-deoxyuridine incorporated into liposomes. Journal of Microencapsulation, 5, 1.
24. TURCOTTE, J.G., SRIVASTAVA, S.P., STEIM, J.M., CALABRESI, P., TIBBETTS, L.M. & CHU, M.Y. (1980). Cytotoxic liponucleotide analogs. II. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinose moiety. Biochimica et Biophysica Acta, 619, 619.
25. YUAN, F., DELLIAN, M., FUKUMURA, D., LEUNIG, M., BERK, D.A., TORCHILIN, V.P. & JAIN, R.K. (1995). Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Research, 55, 3752.